Thermo Fisher Scientific Opens Bay Area Cryo-EM Drug Discovery Center to Accelerate Breakthrough Therapies
核心洞察
Thermo Fisher Scientific (搜索) has opened a new Cryo-Electron Microscopy Drug Discovery Center (搜索) in South San Francisco to provide pharmaceutical and biotechnology companies with advanced cryo-EM (搜索) technologies for accelerated drug development.
Structure-guided drugs developed using cryo-EM (搜索) technology demonstrate more than twice the clinical success rate in half the preclinical time and at half the cost compared to industry standards.
The new center builds on the success of the UK Pharmaceutical Cryo-EM Consortium (搜索) established in 2016, extending this collaborative approach to the North American market with founding customer members.
Thermo Fisher Scientific (搜索) has opened its Cryo-Electron Microscopy (cryo-EM (搜索)) Drug Discovery Center (CDDC) in South San Francisco, providing pharmaceutical and biotechnology innovators with immersive access to advanced cryo-EM technologies designed to accelerate structural insights and the development of life-saving therapies.
Transforming Drug Discovery Through Advanced Technology
The CDDC provides direct access to advanced cryo-EM (搜索) innovation and scientific expertise while significantly lowering barriers to adoption. The technology expands the range of therapeutic targets and advanced therapies for structure-based methods, helping pharmaceutical companies bring drugs to clinics faster.
According to the company, structure-guided drugs have more than twice the rate of clinical success in half the preclinical time and at half the cost, compared with industry standards. This represents a significant advancement in drug development efficiency and cost-effectiveness.
"At Thermo Fisher, so much of what we do is grounded in helping our customers perform research that brings life-saving medicines to patients faster and more effectively," said Glyn Davies, president of Materials & Structural Analysis. "The opening of our Cryo-EM (搜索) Drug Discovery Center creates a collaborative environment where scientists can directly harness the power of Cryo-EM to better understand disease at the molecular level and accelerate therapeutic development."
Expanding Proven Collaboration Model
The new center builds on the success of the UK Pharmaceutical Cryo-EM Consortium (搜索), established in Cambridge, United Kingdom, in 2016. Now celebrating its 10-year anniversary, the consortium represents a longstanding collaboration between Thermo Fisher Scientific (搜索) and five leading pharmaceutical companies.
Modeled after this proven partnership framework, the new U.S.-based CDDC will include founding customer members to extend this collaborative approach to the North American market. The center is strategically located in Oyster Point, in the heart of Bay Area biotechnology innovation.
Strategic Location and Industry Interest
The CDDC combines state-of-the-art cryo-EM (搜索) instrumentation with a collaborative and collegial scientific environment for pharmaceutical and biotechnology innovators looking to expedite the path from discovery to development. A contingent of customers and partners are expected to attend the opening event, underscoring strong industry interest in advancing structure-based drug discovery through cryo-EM technology.
Thermo Fisher Scientific (搜索) Inc., with annual revenue over $40 billion, positions itself as the world leader in serving science. The company's mission focuses on enabling customers to make the world healthier, cleaner and safer through innovative technologies and pharmaceutical services delivered through industry-leading brands including Thermo Scientific (搜索), Applied Biosystems (搜索), Invitrogen (搜索), Fisher Scientific (搜索), Unity Lab Services (搜索), Patheon and PPD.